История выручки, прибыли и денежных потоков из официальной финансовой отчётности.
The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical, toric, and multifocal contact lenses that address vision challenges, such as astigmatism, presbyopia, and myopia. Its CooperSurgical segment focuses on family and women's health care, which provides fertility products and services, medical devices, and contraception, as well as cryostorage, such as cord blood and cord tissue storage.
Интерактивные графики и полная отчётность → Модель оценки (DCF) →
| Отчёт о прибылях и убытках | TTM → 2026-07-31 | 2025-10-31 | 2024-10-31 | 2023-10-31 | 2022-10-31 | 2021-10-31 | 2020-10-31 | 2019-10-31 | 2018-10-31 | 2017-10-31 | 2016-10-31 | 2015-10-31 | 2014-10-31 | 2013-10-31 | 2012-10-31 | 2011-10-31 | 2010-10-31 | 2009-10-31 | 2008-10-31 | 2007-10-31 | 2006-10-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Общая выручка | $4.2B | $4.1B | $3.9B | $3.6B | $3.3B | $2.9B | $2.4B | $2.7B | $2.5B | $2.1B | $2.0B | $1.8B | $1.7B | $1.6B | $1.4B | $1.3B | $1.2B | $1.1B | $1.1B | $951M | $859M |
| Валовая прибыль | $2.7B | $2.5B | $2.6B | $2.4B | $2.1B | $2.0B | $1.5B | $1.8B | $1.6B | $1.4B | $1.2B | $1.1B | $1.1B | $1.0B | $924M | $805M | $677M | $596M | $610M | $520M | $526M |
| Валовая маржа % | 64.7% | 60.7% | 66.6% | 65.6% | 64.7% | 66.9% | 63.1% | 66.2% | 64.5% | 63.8% | 59.6% | 59.6% | 63.5% | 64.7% | 63.9% | 60.5% | 58.4% | 55.2% | 57.4% | 54.6% | 61.2% |
| Операционная прибыль (EBIT) | $544M | $683M | $706M | $533M | $508M | $506M | $312M | $547M | $403M | $429M | $324M | $237M | $306M | $306M | $283M | $228M | $190M | $150M | $127M | $46M | $113M |
| Операционная маржа % | 12.8% | 16.7% | 18.1% | 14.8% | 15.3% | 17.3% | 12.8% | 20.6% | 15.9% | 20.1% | 16.5% | 13.2% | 17.8% | 19.3% | 19.6% | 17.1% | 16.4% | 13.9% | 11.9% | 4.8% | 13.1% |
| Чистая прибыль | $571M | $375M | $392M | $294M | $386M | $2.9B | $238M | $467M | $140M | $373M | $274M | $204M | $270M | $296M | $248M | $175M | $113M | $101M | $65M | ($11M) | $66M |
| Чистая маржа % | 13.5% | 9.2% | 10.1% | 8.2% | 11.7% | 100.8% | 9.8% | 17.6% | 5.5% | 17.4% | 13.9% | 11.3% | 15.7% | 18.6% | 17.2% | 13.2% | 9.7% | 9.3% | 6.2% | -1.2% | 7.7% |
| EBITDA | — | $1.1B | $1.1B | $886M | $879M | $824M | $590M | $826M | $690M | $616M | $520M | $425M | $443M | $447M | $398M | $308M | $255M | $252M | $209M | $140M | $181M |
| Прибыль на акцию (EPS) | $2.93 | $1.87 | $1.96 | $1.48 | $1.94 | $14.77 | $1.20 | $2.33 | $0.70 | $1.88 | $1.40 | $1.03 | $1.38 | $1.49 | $1.26 | $0.91 | $0.61 | $0.55 | $0.35 | $-0.06 | $0.35 |
| Акции в обращении (M) | — | 200M | 200M | 199M | 199M | 199M | 198M | 200M | 199M | 198M | 196M | 197M | 196M | 199M | 197M | 193M | 186M | 182M | 187M | 179M | 190M |
Источник: публичная отчётность компании (SEC). Сверяйте с SEC EDGAR, прежде чем полагаться на любую цифру.
Балансы, денежные потоки, квартальные данные и финансовые коэффициенты — в интерактивном просмотрщике COO. /companies/us/COO
Информация на сайте предназначена исключительно для образовательных и информационных целей и не является инвестиционной рекомендацией. Целевые цены и рекомендации не публикуются.
About TickerBase · Data methodology & sources · Privacy · Terms